linjc16/ctgov huggingface dataset:
Percent Body Fat in Breast Fed Infants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn about normal body composition (% body fat) during the first six months of life in healthy breast-fed babies.

Official Title
-----------------
Developing Normative Body Composition Data in Early Infancy

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term birth Infant must weigh at least 5.5# at birth Single birth Healthy mother/infant as determined by the investigator Intention to breast feed Exclusion Criteria: Significant perinatal morbidity Having health, environmental, or economic constraints on growth Infants of a mother with diabetes or gestational diabetes

Ages Eligible for Study
-----------------
Maximum Age: 2 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Healthy breast fed infants | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Feeding, Body Composition, Body Fat, Infant, Diet, Healthy Infants
Development and Validation for Predicting Inadequate Bowel Preparation

Study Overview
=================
Brief Summary
-----------------
High-quality colonoscopy is considered the gold standard for the detection and prevention of colorectal cancer, and its efficacy is predicated on optimal colon cleansing.However, about 18%-35% of patients were still reported to suffer inadequate bowel preparation. Although several predictive models exist, the current guideline indicates that there is insufficient evidence to recommend the use of a predictive model for clinical practice.

Official Title
-----------------
Development and Validation for Predicting Inadequate Bowel Preparation Before Colonoscopy in Patients

Conditions
-----------------
Polyethylene Glycol, Cathartics, Colonoscopy

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing colonoscopy. patients older than 18 years. Exclusion Criteria: Emergency colonoscopy. Have a serious medical condition, such as heart failure, acute liver failure, severe kidney disease (dialysis or predialysis patients) or New York heart association class iii-iv. Pregnant or breastfeeding. No bowel preparation or poor compliance (no bowel preparation as instructed or laxatives < 90% of prescribed dose). Refuse to sign informed consent. The patient was rescheduled after the previous colonoscopy due to insufficient bowel preparation. Temporarily change to colonoscopy for other reasons. Incomplete colonoscopy due to insufficient parenteral preparation. Lack of complete data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br> | Other: no intervention<br>* no intervention<br>|
| group I<br> | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of bowel preparation | The OBPS is a validated scoring system with scores between 0 and 14, where 0 is the best score. The score comprises a sub score 0-4 for each colon segment: right, transverse and rectosigmoid colon. In addition, a score 0-2 is added to indicate the total amount of luminal fluid. For all participants, OBPS score will be used when the colonscopy is inserting. | A colonoscopy procedure | 
| quality of bowel preparation | The BBPS is another validated scoring system with scores between 0 and 9, where 9 is the best score. The score comprises a sub score 0-3 for each colon segment: right, transverse and left colon. For all participants, BBPS score will be used when colonscopy is withdrawing. | A colonoscopy procedure |
Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to assess whether a new method of quantifying therapy-associated hemodynamic alterations based on DCE MR imaging may help to distinguish pseudoprogression from true progression in patients with high grade glioma, who received CCRT.

Detailed Description
-----------------
Combination temozolomide and radiation significantly prolongs survival compared with radiation alone and has become standard treatment for glioblastoma multiforme (GBM). Response assessment in GBM is difficult as a result of the frequent occurrence of early imaging changes indistinguishable from tumor progression, termed pseudoprogression. The majority of patients remain clinically stable. It is often unclear whether current therapy should be maintained or second-line therapy initiated. The incidence of pseudoprogression after concurrent chemoradiation is15%to 30%. A potential mechanism of pseudoprogression is that radiation-induced vascular changes may lead to focal transient increase in gadolinium enhancement. Dynamic contrast-enhanced (DCE) MR imaging provides a noninvasive means for quantifying tumor vascular properties.

Official Title
-----------------
Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

Conditions
-----------------
High Grade Glioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the patients show the measurable enhancing portion (1 cm in the long diameter according to the RANO criteria) in the immediate f/up MRI after CCRT. Exclusion Criteria: Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the patients do not show the measurable enhancing portion (1 cm in the long diameter according to the RANO criteria) in the immediate f/up MRI after CCRT.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with high-grade glioma<br>Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Permeability Map to Distinguish Progression From Pseudoprogression in High-grade glioma |  | 2year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Permeability Map, High-Grade Glioma
Reconstruction of Hand Soft Tissue Defects

Study Overview
=================
Brief Summary
-----------------
Evaluation of distally based posterior interosseous artery flap in reconstructing hand soft tissue defects that may result from trauma, extensive burns, tumor resection or congenital deformities.

Official Title
-----------------
Reliability and Versatility of Posterior Interosseous Artery Flap in Reconstructing Hand Soft Tissue Defects.

Conditions
-----------------
Hand Injuries

Intervention / Treatment
-----------------
* Procedure: Posterior interosseous artery flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with complex defects over the dorsal and palmar aspect of the wrist and the hand up to the proximal interphalangeal joint level, the whole thumb, and the first web space. Small to moderate hand defects resulting from post-traumatic raw areas, post-traumatic deformities, postburn deformities and scar, post tumor resection, and congenital hand deformity. Availability of a healthy donor site. Exclusion Criteria: Patients with a major uncontrollable medical illness. Chronic heavy smokers. Traumatic injury to the donor site. Complex defects of the hand beyond the PIP joint level.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Hand soft tissue defects<br>Patients with mild to moderate hand soft tissue defects with exposed bone, tendons or cartilage resulting from trauma, tumor ablation or postburn deformities. | Procedure: Posterior interosseous artery flap<br>* The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional and aesthetic outcomes of posterior interosseous artery flap | All patients will be evaluated with objective (functional) and subjective (aesthetic) criteria. Hand functionality will be evaluated using the disability of the arm, shoulder, and hand (DASH) score. The DASH score comprises 30 questions, and the score ranges from 30 points, for no limitation, to 150 points, for maximum limitation. The outcomes will be aesthetically reviewed with scar assessment measured as being good, fair, and poor. This assessment is subjective. Donor site problems are identiﬁed as cold intolerance, numbness, and pain. These will be evaluated as being either present in the patient or non-existent. | 5 months from the end of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Posterior interosseous artery flap, Hand soft tissue defects
Single Center Open Prospective Study for the Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy

Study Overview
=================
Brief Summary
-----------------
The investigators study aim is to determine whether there is a any advantage in starting with upper or lower endoscopy. The main study objective will be the amount of analgesia needed for sustaining the examinee's comfort during the exams. Secondary endpoints will rate of detection of significant pathologies, total time of procedure, examinee's tolerance, time to recovery and examinee's satisfaction.

Conditions
-----------------
Bidirectional Endoscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age> 18 Same day bidirectional endoscopy Exclusion Criteria: Prior failed endoscopy. Any major complication during previous endoscopy. Difficulty in communication with the patients. Psychiatric disease or mental retardation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| examinees undergoing bidirectional endoscopy<br>Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of mephridine and midazolam | Dose of analgestices used in order to achive concious sedation | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to recovery | Time to full recovery and release after endoscopies | 1 year | 
| Rate of significant findings | Rate of significant findings: colonoscopy: polyps, carcinoma, inflammation, diverticuli, A-V malformations Upper endoscopy: Barret's esophagus, severe esophagitis, gastritis, peptic ulcer disease, polyps and space occupying lesions | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastroscopy, Colonoscopy, Anesthesia, Recovery
Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.

Study Overview
=================
Brief Summary
-----------------
To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment group; and to describe the concordance between patient-reported and physician-reported symptom load.

Official Title
-----------------
Epidemiological Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment

Conditions
-----------------
Gastroesophageal Reflux Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with GERD diagnosed clinically or by endoscopy and prescribed with medical treatments Provision of written informed consent Exclusion Criteria: Patients cannot read and/or understand GIS Patients with the history or symptoms of peptic ulcer, gastrointestinal cancer, serious or malignant diseases (anorexia, weight loss, anemia, fever …)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type, frequency and severity of the GERD symptoms |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GERD, reflux symptom, heartburn, acid regurgitation, PPI, H2RA, antacid
Effect of Electroacupuncture on Pain Threshold

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate whether or not electroacupuncture can have an effect on the pain threshold of the subject, as compared to sham treatment.

Detailed Description
-----------------
This study is utilized to evaluate the what effectiveness electroacupuncture has on pain threshold as compared to sham. The outcome measurement utilized will be a digital algometer. The electroacupuncture treatment will consist of a total of four electroacupuncture treatments stimulating acupuncture points LI4 and LI11, and will be given on the same upper extremity tested by the algometer. The algometer measurements will occur alone on the first week, prior to the treatments on the second and third week, and the final reading alone on the fourth week.

Official Title
-----------------
Effect of Electroacupuncture on Pain Threshold

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Device: Electroacupuncture
* Device: Sham electroacupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal healthy subjects Exclusion Criteria: Hypertension Heart Disease Pregnancy No spinal manipulation or other treatment or medication that could effect pain threshold

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electroacupuncture Treatment Group<br>Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness | Device: Electroacupuncture<br>* Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness<br>|
| Sham Comparator: Sham Treatment Group<br>Sham electroacupuncture treatment gives comparison to the experimental group | Device: Sham electroacupuncture<br>* Sham electroacupuncture treatment gives comparison to the experimental group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Digital Algometer |  | Four Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asymptomatic normals
Identification of Entamoeba Spp. in Assuit Governorate Hospitals.

Study Overview
=================
Brief Summary
-----------------
Determination the prevalence of Entamoeba histolytica infections among patients at Assiut University Hospitals presented with diarrhea/dysentery. Evaluatation the role of different cultures in diagnosing Entamoeba . Molecularly differentiation between Entamoeba species to monitor the true prevalence of E.histolytica .

Detailed Description
-----------------
Entamoeba histolytica is a common pathogenic protozoan widely distributed throughout the world (10% of the world's population), with 50,000-100,000 deaths reported annually(1) .It is a health problem both in Egypt and worldwide (2) The disease is more prevalent in densely populated areas with poor hygiene requirements and lacking sanitary water supply, especially in rural areas(3). It causes many digestive complications including diarrhea , and fever(2). it transmits through bloodstream forming abscesses in the brain, eye, liver and other vital organs and tissues or even lead to death in some cases . Some individuals have no symptom of the disease but transmit the infection to others(4) It is well- established that E. histolytica leads to invasive disease in humans. Although both E. dispar and E. moshkovskii are still considered to be non pathogenic and free-living amoebas, respectively, some reports suggest their potential role in provoking disease in humans (5) Cysts of E.dispar , E.moshkovskii and E.hartmanni can be confused with E.histolytica. cysts in the parasitological examination(6) The molecular assays, is preferable as it detects E. histolytica , differentiates it from other species and monitors its true prevalence for better treatment and effective control (2)

Official Title
-----------------
Different Methods for Detection and Identification of Entamoeba Species in Assuit Governorate Hospitals.

Conditions
-----------------
Entamoeba Spp. Identification

Intervention / Treatment
-----------------
* Diagnostic Test: stool sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: : Male and female patients of different age groups with diarrhea/dysentery attending the outpatient clinics at Assiut University Hospitals . Exclusion Criteria: No exclusion criteria .
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination the prevalence of Entamoeba histolytica infections among patients at Assiut University Hospitals presented with diarrhea/dysentery | Different Methods for Detection and Identification of Entamoeba species in Assuit Governorate. | 2022 |
Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis

Study Overview
=================
Brief Summary
-----------------
Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality of life and the delivered quality of care in the hospital.

Detailed Description
-----------------
Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality of life and the delivered quality of care in the hospital during follow-up

Official Title
-----------------
Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis

Conditions
-----------------
Hereditary Haemochromatosis

Intervention / Treatment
-----------------
* Other: Interviews, questionaires, RAND-modified delphi method round


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: phase 1: experts in the field of haemochromatosis (hepatologists, hematologists, endocrinologists, general practitioner, nurses, ...) phase 2: patients with hereditary haemochromatosis, treatment with phlebotomy since 3 months, Dutch/English speaking Exclusion Criteria: patients with secondary iron overload phlebotomy treatment less than 3 months language: no Dutch or English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| quality of life, quality of care<br>hereditary haemochromatosis patients | Other: Interviews, questionaires, RAND-modified delphi method round<br>* phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of quality of life | quality of life | after 3 months of treatment |